#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Prostate cancer Renal disorder Myxofibrosarcoma Oesophageal squamous cell carcinoma stage III Sexually transmitted disease Cryoglobulinaemia Systemic mastocytosis Bronchiectasis Rhabdoid tumour Osteosarcoma metastatic Malignant neoplasm of choroid Chronic graft versus host disease in intestine Measles Ependymoma Transitional cell carcinoma More trials…

    Learn about Rare Diseases

    X-linked lymphoproliferative syndrome – Treatment Soft tissue sarcoma – Life with Disease Waldenstrom’s macroglobulinaemia – Diagnostics Breast angiosarcoma metastatic – Trials in Disease Gastrointestinal stromal tumour – Trials in Disease Congenital hypotransferrinaemia – Basic Information Kearns-Sayre syndrome – Life with Disease Chondrosarcoma metastatic – Treatment Behcet’s syndrome – Diagnostics Bronchopulmonary dysplasia – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Risedronate Sodium Proline Xxb750 Esomeprazole Magnesium Divarasib ZOLPIDEM TARTRATE Bi 1015550 Axicabtagene Ciloleucel Rucaparib Cemdisiran Peppermint Oil Rtp-026 Sodium Lacnotuzumab Lutikizumab KETOROLAC TROMETAMOL Insulin Lispro Progesterone Ph. Eur. Givinostat Adapalene Interferon Gamma More therapies…

    Learn about Your Condition

    Mastocytosis Ectopic pregnancy CDKL5 deficiency disorder Staphylococcal infection Palpitations Polycythaemia vera Cognitive disorder Cystic fibrosis lung Carotid arteriosclerosis Renal cell carcinoma Trigeminal neuralgia Cardiac disorder Left ventricular dysfunction Cardiac sarcoidosis Hodgkin's disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Outpatient Clinic For Specialized Outpatient Medical…

Outpatient Clinic For Specialized Outpatient Medical Care In Endocrinology Dr Albena Dinkova EOOD

Ulitsa Boris Shivachev 14, Pleven, 5801, Bulgaria

Want to learn more about this study or check if you can participate? Contact us.

  • Randomized trial of elecoglipron with dapagliflozin versus placebo in adults with type 2 diabetes mellitus and impaired renal function

    Recruiting

    3 1 1
    Investigated Drugs:
    • Azd5004
    • Dapagliflozin
    Bulgaria Denmark Germany Spain

  • KAI-9531 in Adults With Obesity or Overweight and Diabetes

    Recruiting

    3 1
    Investigated Drugs:
    • HRS 9531
    Bulgaria Czechia Germany Hungary Poland Spain

  • Comparing the efficacy and safety of KAI-9531 and semaglutide in people living with obesity who do not have diabetes

    Recruiting

    3 1 1
    Investigated Diseases:
    • Obesity
    Investigated Drugs:
    • HRS 9531
    • Semaglutide
    Bulgaria Poland

  • A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

    Not recruiting

    3 1
    Investigated Diseases:
    • Cardiovascular disorder
    Investigated Drugs:
    • Cagrilintide
    • Semaglutide
    Bulgaria Denmark France Germany Ireland Italy +3

  • Study on Maridebart Cafraglutide for Adults with Type 2 Diabetes and Obesity or Overweight

    Not recruiting

    3 1
    Investigated Drugs:
    • Maridebart Cafraglutide
    Bulgaria Czechia Germany Hungary Italy Poland

  • Study on How Cagrilintide and Semaglutide Help People with Overweight or Obesity Reduce Weight

    Not recruiting

    3 1
    Investigated Diseases:
    • Obesity
    Belgium Bulgaria Denmark Finland France Germany +4

  • Weight loss in adults with obesity (with or without type 2 diabetes) using cagrilintide and semaglutide: a study of two dose levels versus semaglutide alone

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Obesity
    Investigated Drugs:
    • Cagrilintide
    • Semaglutide
    Austria Belgium Bulgaria Czechia France Greece +8

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!